Compare Amylx Pharmaceuticals Inc (AMLX) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Trip.com Group Ltd — how do they compare? Amylx Pharmaceuticals Inc trades at $17.29 (market cap $1.98B), while Trip.com Group Ltd trades at $42.49 (market cap $26.45B). The key difference: Trip.com Group Ltd is far larger — about 13.4× Amylx Pharmaceuticals Inc's market cap, and Trip.com Group Ltd pays a 0.57% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | TCOM | |
|---|---|---|
Market Cap | $1.98B | $26.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $78.96 |
52-Week Low | $7.64 | $39.84 |
Enterprise Value | $1.70B | $19.15B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Trip.com Group (TCOM) trades at $42.80, up 3.31% on the day, with strong fundamentals including a P/E of 6.43 and net income margin of 48.65%. The stock faces technical headwinds with a bearish signal from moving averages and RSI at 82.74 suggesting overbought conditions. Recent Q1 2026 earnings missed expectations at $0.83 vs. $0.85, while revenue guidance for Q2 2026 of 3%-8% growth disappointed investors, triggering an 18% selloff on June 29, 2026.
Despite near-term pressure from regulatory scrutiny and conservative guidance, Trip.com maintains robust profitability and analyst consensus of $56.72 price target with 67% buy ratings. The company's dominant position in China's travel market and strong cash flow generation provide long-term upside potential, though regulatory risks and margin compression remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
